

FOI 1964

25.10.2023

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Q1. How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- **ALK Inhibitors (Alectinib – 3, Brigatinib – 0, Ceritinib – 0, Crizotinib– 0, Lorlatinib – 0)**
- **Amivantamab – 0**
- **Atezolizumab Monotherapy- 2**
- **Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel - 0**
- **Dabrafenib + Trametinib – 0**
- **Docetaxel monotherapy or in combination with Carboplatin/Cisplatin – 5**
- **Durvalumab – 2**
- **Gemcitabine – 2**
- **Nitedanib + Docetaxel – 0**
- **Nivolumab – 0**
- **Osimertinib - 7**
- **Other EGFR Inhibitors (Afatinib – 0, Erlotinib – 1, Gefitinib – 0, Dacomitinib – 0, Mobocertinib – 1)**
- **Paclitaxel - 4**
- **Pembrolizumab Monotherapy - 16**
- **Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) – 0**
- **Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) - 1**
- **Pemetrexed + Platinum (Carboplatin/Cisplatin) – 7**
- **RET Inhibitors (Pralsetinib, Selpercatinib) - 0**
- **Sotorasib – 0**
- **Tepotinib – 0**
- **Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin – 0**
- **Other active systemic anti-cancer therapy – 0**
- **Palliative care only – not held**

Q2. Does your trust/health board participate in any clinical trials for non-small cell lung cancer (NSCLC)? If so, could you please provide the name of each active trial and the number of patients taking part. – No clinical trials.

Email: Foi.Team@Southerntrust.hscni.net